Post-lumpectomy intracavitary retention and lymph node targeting of 99mTc-encapsulated liposomes in nude rats with breast cancer xenograft

Shihong Li, Beth Goins, William T Phillips, Marcela Saenz, Pamela M Otto, Ande Bao

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Liposomes are recognized drug delivery systems with tumor-targeting capability. In addition, therapeutic or diagnostic radionuclides can be efficiently loaded into liposomes. This study investigated the feasibility of utilizing radiotherapeutic liposomes as a new post-lumpectomy radiotherapy for early-stage breast cancer by determining the locoregional retention and systemic distribution of liposomes radiolabeled with technetium-99m (99mTc) in an orthotopic MDA-MB-231 breast cancer xenograft nude rat model. To test this new brachytherapy approach, a positive surgical margin lumpectomy model was set up by surgically removing the xenograft and deliberately leaving a small tumor remnant in the surgical cavity. Neutral, anionic, and cationic surface-charged fluorescent liposomes of 100 and 400 nm diameter were manufactured and labeled with 99mTc-BMEDA. Locoregional retention and systemic distribution of 99mTc-liposomes injected into the post-lumpectomy cavity were determined using non-invasive nuclear imaging, ex vivo tissue gamma counting and fluorescent stereomicroscopic imaging. The results indicated that 99mTc-liposomes were effectively retained in the surgical cavity (average retention was 55.7 ± 24.2% of injected dose for all rats at 44 h post-injection) and also accumulated in the tumor remnant (66.9 ± 100.4%/g for all rats). The majority of cleared 99mTc was metabolized quickly and excreted into feces and urine, exerting low radiation burden on vital organs. In certain animals 99mTc-liposomes significantly accumulated in the peripheral lymph nodes, especially 100 nm liposomes with anionic surface charge. The results suggest that post-lumpectomy intracavitary administration of therapeutic radionuclides delivered by 100-nm anionic liposome carrier is a potential therapy for the simultaneous treatmentof the surgical cavity and the draining lymph nodes of early-stage breast cancer.

Original languageEnglish (US)
Pages (from-to)97-107
Number of pages11
JournalBreast Cancer Research and Treatment
Volume130
Issue number1
DOIs
StatePublished - Nov 2011

Fingerprint

Nude Rats
Segmental Mastectomy
Heterografts
Liposomes
Lymph Nodes
Breast Neoplasms
Radioisotopes
Neoplasms
Technetium
Brachytherapy
Feasibility Studies
Drug Delivery Systems
Feces
Radiotherapy
Therapeutics
Urine
Radiation

Keywords

  • Brachytherapy
  • Breast cancer
  • Intracavitary
  • Locoregional retention
  • Lymph node
  • Radioactive liposomes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Post-lumpectomy intracavitary retention and lymph node targeting of 99mTc-encapsulated liposomes in nude rats with breast cancer xenograft. / Li, Shihong; Goins, Beth; Phillips, William T; Saenz, Marcela; Otto, Pamela M; Bao, Ande.

In: Breast Cancer Research and Treatment, Vol. 130, No. 1, 11.2011, p. 97-107.

Research output: Contribution to journalArticle

@article{81052cfa07c44247b6141b8572e17259,
title = "Post-lumpectomy intracavitary retention and lymph node targeting of 99mTc-encapsulated liposomes in nude rats with breast cancer xenograft",
abstract = "Liposomes are recognized drug delivery systems with tumor-targeting capability. In addition, therapeutic or diagnostic radionuclides can be efficiently loaded into liposomes. This study investigated the feasibility of utilizing radiotherapeutic liposomes as a new post-lumpectomy radiotherapy for early-stage breast cancer by determining the locoregional retention and systemic distribution of liposomes radiolabeled with technetium-99m (99mTc) in an orthotopic MDA-MB-231 breast cancer xenograft nude rat model. To test this new brachytherapy approach, a positive surgical margin lumpectomy model was set up by surgically removing the xenograft and deliberately leaving a small tumor remnant in the surgical cavity. Neutral, anionic, and cationic surface-charged fluorescent liposomes of 100 and 400 nm diameter were manufactured and labeled with 99mTc-BMEDA. Locoregional retention and systemic distribution of 99mTc-liposomes injected into the post-lumpectomy cavity were determined using non-invasive nuclear imaging, ex vivo tissue gamma counting and fluorescent stereomicroscopic imaging. The results indicated that 99mTc-liposomes were effectively retained in the surgical cavity (average retention was 55.7 ± 24.2{\%} of injected dose for all rats at 44 h post-injection) and also accumulated in the tumor remnant (66.9 ± 100.4{\%}/g for all rats). The majority of cleared 99mTc was metabolized quickly and excreted into feces and urine, exerting low radiation burden on vital organs. In certain animals 99mTc-liposomes significantly accumulated in the peripheral lymph nodes, especially 100 nm liposomes with anionic surface charge. The results suggest that post-lumpectomy intracavitary administration of therapeutic radionuclides delivered by 100-nm anionic liposome carrier is a potential therapy for the simultaneous treatmentof the surgical cavity and the draining lymph nodes of early-stage breast cancer.",
keywords = "Brachytherapy, Breast cancer, Intracavitary, Locoregional retention, Lymph node, Radioactive liposomes",
author = "Shihong Li and Beth Goins and Phillips, {William T} and Marcela Saenz and Otto, {Pamela M} and Ande Bao",
year = "2011",
month = "11",
doi = "10.1007/s10549-010-1309-x",
language = "English (US)",
volume = "130",
pages = "97--107",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Post-lumpectomy intracavitary retention and lymph node targeting of 99mTc-encapsulated liposomes in nude rats with breast cancer xenograft

AU - Li, Shihong

AU - Goins, Beth

AU - Phillips, William T

AU - Saenz, Marcela

AU - Otto, Pamela M

AU - Bao, Ande

PY - 2011/11

Y1 - 2011/11

N2 - Liposomes are recognized drug delivery systems with tumor-targeting capability. In addition, therapeutic or diagnostic radionuclides can be efficiently loaded into liposomes. This study investigated the feasibility of utilizing radiotherapeutic liposomes as a new post-lumpectomy radiotherapy for early-stage breast cancer by determining the locoregional retention and systemic distribution of liposomes radiolabeled with technetium-99m (99mTc) in an orthotopic MDA-MB-231 breast cancer xenograft nude rat model. To test this new brachytherapy approach, a positive surgical margin lumpectomy model was set up by surgically removing the xenograft and deliberately leaving a small tumor remnant in the surgical cavity. Neutral, anionic, and cationic surface-charged fluorescent liposomes of 100 and 400 nm diameter were manufactured and labeled with 99mTc-BMEDA. Locoregional retention and systemic distribution of 99mTc-liposomes injected into the post-lumpectomy cavity were determined using non-invasive nuclear imaging, ex vivo tissue gamma counting and fluorescent stereomicroscopic imaging. The results indicated that 99mTc-liposomes were effectively retained in the surgical cavity (average retention was 55.7 ± 24.2% of injected dose for all rats at 44 h post-injection) and also accumulated in the tumor remnant (66.9 ± 100.4%/g for all rats). The majority of cleared 99mTc was metabolized quickly and excreted into feces and urine, exerting low radiation burden on vital organs. In certain animals 99mTc-liposomes significantly accumulated in the peripheral lymph nodes, especially 100 nm liposomes with anionic surface charge. The results suggest that post-lumpectomy intracavitary administration of therapeutic radionuclides delivered by 100-nm anionic liposome carrier is a potential therapy for the simultaneous treatmentof the surgical cavity and the draining lymph nodes of early-stage breast cancer.

AB - Liposomes are recognized drug delivery systems with tumor-targeting capability. In addition, therapeutic or diagnostic radionuclides can be efficiently loaded into liposomes. This study investigated the feasibility of utilizing radiotherapeutic liposomes as a new post-lumpectomy radiotherapy for early-stage breast cancer by determining the locoregional retention and systemic distribution of liposomes radiolabeled with technetium-99m (99mTc) in an orthotopic MDA-MB-231 breast cancer xenograft nude rat model. To test this new brachytherapy approach, a positive surgical margin lumpectomy model was set up by surgically removing the xenograft and deliberately leaving a small tumor remnant in the surgical cavity. Neutral, anionic, and cationic surface-charged fluorescent liposomes of 100 and 400 nm diameter were manufactured and labeled with 99mTc-BMEDA. Locoregional retention and systemic distribution of 99mTc-liposomes injected into the post-lumpectomy cavity were determined using non-invasive nuclear imaging, ex vivo tissue gamma counting and fluorescent stereomicroscopic imaging. The results indicated that 99mTc-liposomes were effectively retained in the surgical cavity (average retention was 55.7 ± 24.2% of injected dose for all rats at 44 h post-injection) and also accumulated in the tumor remnant (66.9 ± 100.4%/g for all rats). The majority of cleared 99mTc was metabolized quickly and excreted into feces and urine, exerting low radiation burden on vital organs. In certain animals 99mTc-liposomes significantly accumulated in the peripheral lymph nodes, especially 100 nm liposomes with anionic surface charge. The results suggest that post-lumpectomy intracavitary administration of therapeutic radionuclides delivered by 100-nm anionic liposome carrier is a potential therapy for the simultaneous treatmentof the surgical cavity and the draining lymph nodes of early-stage breast cancer.

KW - Brachytherapy

KW - Breast cancer

KW - Intracavitary

KW - Locoregional retention

KW - Lymph node

KW - Radioactive liposomes

UR - http://www.scopus.com/inward/record.url?scp=82455218977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455218977&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-1309-x

DO - 10.1007/s10549-010-1309-x

M3 - Article

C2 - 21181436

AN - SCOPUS:82455218977

VL - 130

SP - 97

EP - 107

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -